Bicycle Therapeutics plc has announced several upcoming milestones and data presentations for its clinical programs and radiopharmaceutical pipeline. In the first quarter of 2026, the company plans to provide an update on dose selection from its Phase 2/3 Duravelo-2 pivotal trial and the potential approval pathway for zelenectide pevedotin in metastatic urothelial cancer, following discussions with regulatory agencies. Initial data from the Phase 1/2 Duravelo-3 trial evaluating zelenectide pevedotin in NECTIN4 amplified breast cancer are expected in the second half of 2026. Additional Phase 1 data for BT7480 in combination with nivolumab, as well as for BT5528 in combination with nivolumab in metastatic urothelial cancer, are expected to be presented at scientific conferences in the first half of 2026. Bicycle Therapeutics also plans to report further human imaging data from its EphA2 radiopharmaceutical program and provide updates on future clinical development for BT5528 in the first half of 2026. The company presented new imaging data for an early radioconjugate molecule targeting MT1-MMP at the 2025 AACR Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicycle Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112615560) on January 12, 2026, and is solely responsible for the information contained therein.